Literature DB >> 6462443

Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons.

L A Chiodo, M J Bannon, A A Grace, R H Roth, B S Bunney.   

Abstract

Electrophysiological and biochemical techniques were used to study midbrain dopamine systems. In the electrophysiological studies, projection areas of individual dopaminergic cells were identified by antidromic activation. Dopamine cells which innervate the piriform cortex and those that innervate the caudate nucleus demonstrated their usual dose-dependent inhibitory response to both the intravenous administration of the direct-acting dopamine agonist apomorphine and the microiontophoretic application of dopamine. In contrast, the firing rate of dopamine neurons which project to the prefrontal cortex and of those terminating in the cingulate cortex was not altered by either the intravenous administration of low to moderate doses of apomorphine or microiontophoretically applied dopamine. The mean basal discharge rate and degree of burst firing was also different between these subgroups of midbrain dopaminergic neurons. Mesoprefrontal and mesocingulate dopamine neurons had mean firing rates of 9.3 and 5.9 spikes/s respectively, and showed intense burst activity. Mesopiriform and nigrostriatal dopamine cells had discharge rates of 4.3 and 3.1 spikes/s and displayed only moderate bursting. The dopaminergic nature of those mesocortical neurons insensitive to apomorphine and dopamine was confirmed using combined intracellular recording and catecholamine histofluorescence techniques. Thus, after the intracellular injection of colchicine and subsequent processing for glyoxylic acid-induced histofluorescence, the injected cells could be identified by their brighter fluorescences compared to the surrounding, normally fluorescing, non-injected dopamine neurons. Using biochemical techniques, subgroups of midbrain dopaminergic systems were again found to differ. The administration of gamma-butyrolactone increased dopamine levels in all areas sampled (prefrontal, cingulate and piriform cortices as well as the caudate nucleus). However, although this effect was readily reversed in both the piriform cortex and caudate nucleus by pretreatment with apomorphine, this treatment had no effect on the increased dopamine levels observed in the prefrontal and cingulate cortices. In addition, the decline in dopamine levels after synthesis inhibition with alpha-methyltyrosine was significantly faster in the prefrontal and cingulate cortices relative to the caudate nucleus. The piriform cortex showed an intermediate decline which was not significantly different from that observed in any of the other regions.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6462443     DOI: 10.1016/0306-4522(84)90133-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  71 in total

1.  I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain.

Authors:  Henrike Neuhoff; Axel Neu; Birgit Liss; Jochen Roeper
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

Review 2.  Dopamine tunes prefrontal outputs to orchestrate aversive processing.

Authors:  Caitlin M Vander Weele; Cody A Siciliano; Kay M Tye
Journal:  Brain Res       Date:  2018-12-01       Impact factor: 3.252

3.  Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum.

Authors:  S J Cragg; S A Greenfield
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

4.  Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances.

Authors:  Zayd M Khaliq; Bruce P Bean
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

5.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

Review 7.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.

Authors:  D Galter; K Pernold; T Yoshitake; E Lindqvist; B Hoffer; J Kehr; N-G Larsson; L Olson
Journal:  Genes Brain Behav       Date:  2009-10-07       Impact factor: 3.449

9.  In vivo release of dopamine from rat striatum, substantia nigra and prefrontal cortex: differential modulation by baclofen.

Authors:  M Santiago; A Machado; J Cano
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 10.  The role of D2-autoreceptors in regulating dopamine neuron activity and transmission.

Authors:  C P Ford
Journal:  Neuroscience       Date:  2014-01-23       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.